Navigation Links
CX41 Microscopes

ProductsCX41 Microscopes
Company Olympus America Diagnostics
Item CX41 Microscopes
Features Solid, easy to operate and reliable for routine clinical and educational users. Newly-developed infinity corrected Plan C Achromat objectives offer exceptional flatness producing sharp, clear images right up the edge of the field of view (4x, 10x, 40x, 100x oil). Anti-fungus treatment helps protect optical parts even in high humidity regions. Inward-facing, quintuple revolving nosepiece improves access and makes for quick, easy slide changes. Fixed Abbe condenser N.A. 1.25, centerable and focusable for Khler illumination. A 6V/30W halogen bulb provides ample illumination for any observation. Ergonomically designed frame with low positioned coarse and fine focusing controls, analyzer slot for linear polarized light, and convenient handgrips at the front and back for transportation; integrated field stop. Built in left or right hand stage with rackless design, low positioned X,Y controls with ergogrips to facilitate operation.
Description The CX41 continue the outstanding worldwide reputation of the CH2 microscopes in medical and educational arenas, now with UIS infinity-corrected optics. The CX models improve all-around performance and even greater cost efficiency over previous models.
Info Olympus America DiagnosticsCall Olympus America Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-651-9837

Customer Service: 1-800-645-8160, 610-391-2479

Related medicine products :

1. CX31 Microscopes
2. CKX31 Microscopes
3. CKX41 Microscopes
4. Cole-Parmer Stereozoom Fluorescent Microscopes
5. Cole-ParmerHigh-Power Stereozoom Fluorescent Microscopes
6. Neuro Surgical Microscopes
7. SZ61/SZ51 Zoom Stereo Microscopes
(Date:5/24/2013)... 2013 Gift Card Network members ... in sustainable card material, are combining forces to ... as a sustainable gift card substrate. , The ... challenges and increase education and usage of these ... the reduction of carbon footprint and environmental impact ...
(Date:5/24/2013)... May 24, 2013 Let’s face it: very ... not uncommon for the majority of people to be uncomfortable ... due to a coffee addiction or simply genetics, yellowish or ... are so popular. , Herald Square Dental is ... effective whitening system: Venus White Max. , Teeth become ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... to the development of infantile myofibromatosis (IM)a disorder characterized ... tissuemay provide new therapeutic targets, according to researchers from ... findings, published in the American Journal of Human ... this debilitating disease, for which the only current treatment ... IM is an inheritied disorder that develops in infancy ...
(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
... , WEDNESDAY, Feb. 23 (HealthDay News) -- The main ... regain their ability to taste and enjoy food, according to ... could potentially lead to treatments to help some cancer patients ... to smell and taste food, which can cause them to ...
... a factory or at a rock concert, noise-induced hearing loss ... Researchers at Washington University School of Medicine in St. Louis ... in mice when given before they are exposed to loud ... hearing loss after noise exposure. While both drugs are ...
... - Understanding the genetics of bipolar disorder could lead ... with this disorder has been challenging. A ... brain protein called Piccolo in the risk for inheriting ... is a member of a protein family that includes ...
... percent of the world,s population is currently infected by hepatitis ... cirrhosis and liver cancer, and it,s the most frequent cause ... we have no traditional vaccine, but researchers at the University ... a vaccine, which provides future hope for medical protection from ...
... , WEDNESDAY, Feb. 23 (HealthDay News) -- People,s ... to stress, according to a new study. To reach ... make a speech in a laboratory in front of a ... responses were monitored during the speech, and they were later ...
... after having early-stage breast cancer, but they are at ... a new cancer, in either breast. Annual screening (a.k.a. ... but only scant evidence on screening outcomes supported this ... the American Medical Association , the most comprehensive relevant ...
Cached Medicine News:Health News:Pot Ingredient May Restore Appetite After Chemo 2Health News:2 drugs protect hearing better than 1 2Health News:A new clue to the genetics of bipolar disorder: Piccolo 2Health News:New vaccine technology protects mice from hepatitis C virus 2Health News:New vaccine technology protects mice from hepatitis C virus 3Health News:New vaccine technology protects mice from hepatitis C virus 4Health News:Screening mammograms catch second breast cancers early 2
(Date:5/24/2013)...  An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3